Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy

R M Pascale1, M M Simile, F Feo

  • 1Istituto di Patologia Generale dell' Universita di Sassari, Italy.

Anticancer Research
|September 1, 1993
PubMed

Insights

Epigenetic alterations, including DNA hypomethylation, play a crucial role in liver cancer development. Supplementation with S-adenosyl methionine (SAM) can reverse these changes and prevent tumor formation in rats.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Epigenetics

Background:

  • Carcinogenesis involves oncogene activation, suppressor gene inactivation, and epigenetic modifications.
  • Ras gene mutations are common in mouse liver tumors, while c-myc amplification and p53 mutations occur in rodent and human liver carcinogenesis.
  • DNA hypomethylation is implicated in carcinogenesis, leading to overexpression of growth-related genes.

Purpose of the Study:

  • To investigate the role of DNA methylation and S-adenosyl methionine (SAM) in liver carcinogenesis.
  • To evaluate the potential of modulating epigenetic mechanisms for cancer chemoprevention.

Main Methods:

  • Analysis of gene mutations (ras, c-myc) and suppressor gene alterations (p53) in rodent liver tumors.
  • Assessment of DNA methylation status and S-adenosyl methionine/S-adenosylhomocysteine (SAM/SAH) ratio in rat liver.
  • Administration of methyl-deficient diets and exogenous SAM or 5-azacytidine to rats to study their effects on carcinogenesis and gene expression.

Main Results:

  • Mutational activation of ras genes is frequent in mouse liver tumors, while c-myc amplification and p53 mutations are observed in rat and human liver cancers.
  • A decreased SAM/SAH ratio and DNA hypomethylation are associated with preneoplastic liver tissue development.
  • Exogenous SAM administration restored SAM/SAH ratio, increased DNA methylation, inhibited growth-related gene expression, and prevented tumor development in rats; this effect was abolished by 5-azacytidine.

Conclusions:

  • Epigenetic alterations, particularly DNA hypomethylation and altered SAM/SAH ratio, are critical in liver carcinogenesis.
  • SAM supplementation demonstrates chemopreventive effects by restoring DNA methylation and inhibiting oncogene expression.
  • Modulating epigenetic mechanisms, such as DNA methylation, offers a promising strategy for liver cancer chemoprevention.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...